MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$129,693K
(3.00%↑ Y/Y)
Net loss
-$122,931K
(9.61%↑ Y/Y)
Unrealized (gain) loss on
marketable securities
-$6,730K
(-398.58%↓ Y/Y)
Foreign currency
translation adjustment
-$32K
(-178.05%↓ Y/Y)
Other income, net
$8,156K
(-39.75%↓ Y/Y)
Net loss before
income taxes
-$122,092K
(9.49%↑ Y/Y)
Provision for income taxes
$839K
(-24.35%↓ Y/Y)
Total other income,
net
$8,156K
(-39.75%↓ Y/Y)
Collaboration Revenue
$1,000K
Grant
$458K
Loss from operations
-$130,248K
(12.25%↑ Y/Y)
Total revenue
$1,458K
(68.55%↑ Y/Y)
Total operating
expenses
$131,706K
(-11.78%↓ Y/Y)
Research and development
expense
$68,574K
(-5.39%↓ Y/Y)
Collaboration expense, net
$45,949K
(-20.10%↓ Y/Y)
General and
administrative
$17,183K
(-10.95%↓ Y/Y)
Back
Back
Income Statement
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)
source: myfinsight.com